Stealth BioTherapeutics

Stealth BioTherapeutics announces the Mito Assist™ Patient Support Program and a partnership with AnovoRx Specialty Pharmacy.  The initiative underscores Stealth’s ongoing commitment to patient access and partnership with the Barth syndrome community. Learn more in our press release: https://lnkd.in/eDzE5iNr

On behalf of the #BarthSyndrome patient community, we are thrilled to share that the FDA has approved our medicine as the first-ever treatment for this ultra-rare, life-threatening disease. This approval also marks the first FDA approved mitochondria-targeted medicine. Learn more: https://lnkd.in/efvtjx9u #MitochondrialDisease #RareDisease

Stealth is honored to be named one of the #XPRIZEHealthspan semifinalists! Tune into the awards livestream tonight 5/12 at 6pm ET to learn more about the cool work XPRIZE does and how this year’s award nominees are revolutionizing the way we think about human health. https://bit.ly/3F1chBM

Stealth is looking forward to attending the annual Retina World Congress, taking place May 8-11, where we'll share highlights from our clinical development program in #dryAMD including the trial design of our Phase 3 ReNEW and ReGAIN trials. Our CEO, Reenie McCarthy, will also be presenting at the Retina Unplugged session and panel happening today at 9:50am ET! #RetinaWorldCongress

Stealth BioTherapeutics announces upcoming data presentations at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. #ARVO2025   Read the full press release for more details: https://bit.ly/42MnBtB

We’re excited to share that our CEO, Reenie McCarthy, will be speaking on April 24th at the World Orphan Drug Congress USA 2025 at 12:00 PM on the panel: "Finding the optimal pathway to market and moving the bar for regulatory approval."    Bringing rare disease therapies to patients requires navigating a complex and evolving regulatory landscape. This panel will explore accelerated approval pathways, adaptive trial designs, and breakthrough therapy designations, discussing how to get innovative treatments to market faster, without compromising on safety or efficacy.

Barth Syndrome Awareness Day is celebrated around the world on April 5th to bring together all members of this ultra-rare disease community! Stealth is proud to work with such a resilient and steadfast group of individuals who continue to increase awareness of Barth syndrome.   Learn more about #BarthSyndromeAwarenessDay and how you can get involved here: http://bit.ly/3zzTjfm 

Attending the Informa Connect #RareDiseaseSummit in Philadelphia today? Be sure to check out Stealth's CEO, Reenie McCarthy, this afternoon as she presents at the pioneering perspectives spotlight session. Learn more here: https://bit.ly/3FKe6TC

Stealth is pleased to announce that 50% enrollment has been met in the ReNEW clinical trial evaluating patients with dry age-related macular degeneration! Thank you to all the ReNEW investigators and staff for your steadfast efforts in reaching this important milestone. Read the full press release here: https://bit.ly/41SDopY A special thank you to our ReNEW Trial Scientific Review Committee: Charles Wykoff (Chair), Carl Regillo and Michael Singer. Additional gratitude to our Scientific Advisory Board members; Charles Wykoff, David Brown, David Boyer, MD, Arshad M. Khanani, David Lally, Justis Ehlers, Peter Kaiser, and Jeff Heier for your trial design expertise and guidance as we aim to bring novel therapies to patients living with this devastating disease. #DryAMD https://bit.ly/41SDopY

Today is Rare Disease Day!! At Stealth, our mission is to lead the development of mitochondrial medicine to improve the lives of patients living with ultra-rare and rare diseases. Join us in raising awareness for the 300 million people living with a rare disease all around the world. Get involved at: https://lnkd.in/dgtircHT   #BarthSyndrome #PrimaryMiotchondrialMyopathy #FriedreichsAtaxia